Table 1 Baseline characteristics of the two group patients

Gender

 Male

 Female

91 (88.3%)

12 (11.7%)

57 (93.4%)

4 (6.6%)

0.288

Age, years (median, SD)

52.0, 8.82

56.0, 7.88

0.115

ECOG score

 0–1

 2

96 (93.2%)

7 (6.8%)

58 (95.1%)

3 (4.9%)

0.627

BCLC

 B

 C

4 (3.8%)

99 (96.2%)

2 (3.3%)

59 (96.7%)

0.842

Child-Pugh

 A

 B

84 (81.6%)

19 (18.4%)

50 (82.0%)

11 (18.0%)

0.947

Viral status

 HBV

 others

93 (90.3%)

10 (9.7%)

58 (95.1%)

3 (4.9%)

0.272

Tumor size, cm (Mean)

 ≥ 10 cm

 < 10 cm

71 (68.9%)

32 (31.1%)

45 (73.8%)

16 (26.2%)

0.510

Portal vein invasion

Absent

 VP1-2

 VP3

 VP4

9 (8.7%)

5 (4.9%)

19 (18.4%)

70 (68.0%)

4 (6.6%)

5 (8.2%)

9 (14.8%)

43 (70.4%)

0.882

Venous invasion

 Absent

 Present

76 (73.8%)

27 (26.2%)

50 (82%)

11 (18%)

0.230

Extrahepatic spread

 Absent

 Present

71 (68.9%)

32 (31.1%)

41 (67.2%)

20 (32.8%)

0.819

Tumor number

 Single

 Multiple

39 (37.9%)

64 (62.1%)

25 (41%)

36 (59%)

0.692

AFP, ng/ml(Mean)

 ≤ 400

 > 400

33 (32.0%)

70 (68.0%)

26 (42.6%)

35 (57.4%)

0.172

High-risk type

 VP4

 TO 50%

 Both

54 (52.4%)

33 (32.1%)

16 (15.5%)

31 (50.8%)

18 (29.5%)

12 (19.7%)

0.802

PD-1 inhibition agent

 Camrelizumab

 Tislelizumab

 Sintilimab

62 (60.2%)

26 (25.2%)

15 (14.6%)

32 (52.5%)

20 (32.8%)

9 (14.7%)

0.694

ALBI grade

 I

 II

 III

54 (52.4%)

47 (45.7%)

2 (1.9%)

25 (41.0%)

33 (54.1%)

3 (4.9%)

0.257

Laboratory tests

TBil, µmol/L (Mean, SD)

Albumin, g/L (Mean, SD)

Platelet, ×109/L (Mean, SD)

WBC, ×109/L (Mean, SD)

PT, seconds (Mean, SD)

Creatinine, µmol/L (Mean, SD)

ALT, IU/L (Mean, SD)

AST, IU/L (Mean, SD)

21.4, 12.3

38.4, 4.2

180.6, 78.6

6.0, 1.8

12.1, 1.1

65.5, 12.4

89.4, 55.9

58.1, 39.9

23.4, 14.4

39.3, 6.6

192.9, 86.6

6.4, 2.8

12.1, 1.1

75.0, 85.7

77.7, 38.6

49.9, 28.4

0.473

0.440

0.479

0.469

0.991

0.340

0.713

0.603